{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-046031","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2021-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.103101+00:00","generated_at":"2026-06-29T07:20:20.055755+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CSO Jane Gross to resign Sept 14, 2021; will consult through Dec 31, 2021","bullets":["Jane Gross resigns as Chief Scientific Officer effective Sept 14, 2021; transitions to consultant through Dec 31, 2021.","Receives lump-sum $166,000 cash payment by Jan 7, 2022; hourly rate for transition hours beyond stated limit.","Vested stock options exercisable for 90 days from Jan 1, 2022.","Non-compete and non-solicitation obligations for 12 months following last day of employment.","Company has commenced search for a new Chief Scientific Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-046031","json":"https://secwatch.observer/filing/0001564590-21-046031.json","markdown":"https://secwatch.observer/filing/0001564590-21-046031.md","text":"https://secwatch.observer/filing/0001564590-21-046031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000156459021046031/0001564590-21-046031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000156459021046031/apvo-8k_20210825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T07:20:20.055755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b3ca76116","claim":"Jane Gross resigned as Chief Scientific Officer at Aptevo Therapeutics Inc..","evidence_excerpt":"On August 25, 2021, Jane Gross (“Gross”) resigned as the Chief Scientific Officer of Aptevo Therapeutics Inc. (the “Company”) effective September 14, 2021 (“Separation Date”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000156459021046031/0001564590-21-046031-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}